Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Payables (2016 - 2025)

Vycor Medical has reported Payables over the past 16 years, most recently at $3.3 million for Q4 2025.

  • Quarterly Payables rose 8.62% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 8.62% year-over-year, with the annual reading at $3.3 million for FY2025, 8.62% up from the prior year.
  • Payables was $3.3 million for Q4 2025 at Vycor Medical, down from $3.4 million in the prior quarter.
  • Over five years, Payables peaked at $3.4 million in Q3 2025 and troughed at $426773.0 in Q2 2023.
  • The 5-year median for Payables is $552660.5 (2021), against an average of $1.7 million.
  • Year-over-year, Payables dropped 22.18% in 2023 and then soared 581.33% in 2024.
  • A 5-year view of Payables shows it stood at $548593.0 in 2021, then decreased by 4.35% to $524755.0 in 2022, then surged by 417.7% to $2.7 million in 2023, then rose by 12.89% to $3.1 million in 2024, then increased by 8.62% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Payables are $3.3 million (Q4 2025), $3.4 million (Q3 2025), and $3.2 million (Q2 2025).